Clinical trial · Interventional
Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background: The effect of existing treatment modalities of extensive disease small-cell lung cancer (ED-SCLC) is unsatisfactory. Progress of new strategies including more efficient therapy is wanted. Endostar® (Rh-endostatin Injection) may have anti-tumor activity by against vascular endothelial growth factor for initial treatment. This study was designed to evaluate the safety and efficacy of Endostar® combined with etoposide-carboplatin (EC) chemotherapy in patients with ED-SCLC seeking for more effective treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endostar | Drug | — | UNRESOLVED |
| Etoposide-Carboplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Etoposide-Carboplatin with Endostar
- description
- Endostar® 7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
- interventionNames
- Drug: Endostar
- Drug: Etoposide-Carboplatin
- type
- ACTIVE_COMPARATOR
- label
- Etoposide-Carboplatin
- description
- Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
- interventionNames
- Drug: Etoposide-Carboplatin
Primary outcomes (1)
- measure
- Progression free survival (PFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically diagnosed SCLC; * Age of 18-75 years; * Life expectancy \> 3 months; * Adequate hematologic, renal, and hepatic function; * ECOG PS 0-2; Exclusion Criteria: * Brain metastases; * Clinically significant cardiovascular disease; * Presence of hepatic and renal dysfunction; * Evidence of bleeding diathesis or coagulopathy * Pregnant or lactating woman;
References
Publications (0)
Data not yet available